Oral Sucrose Provides Effective Pain Relief for Newborn Venepuncture Procedures

Simple Sweet Solution Shows Measurable Pain Relief in Newborn Venepuncture

A 2026 Cochrane review of 29 randomized trials involving more than 2,700 preterm and full‑term infants found that oral sucrose likely reduces pain during venepuncture and in the first minute after needle insertion when compared with no intervention, water, or routine comfort care. Sucrose appeared more effective than pacifiers, while evidence versus skin‑to‑skin care was limited. No trials in the review reported harmful events such as gagging or apnoea. Wide variation in dosing and delivery methods was documented across studies, underscoring the need for clear local protocols. The full analysis is available in the Cochrane Database of Systematic Reviews (DOI: 10.1002/14651858.CD015221.pub2).

“Newborn babies undergo frequent needle procedures in hospital without any pain relief or comforting measures, even though older children and adults rarely have these procedures done without pain care.”

“The evidence shows that a small amount of sucrose given just before the procedure is a simple, fast, and effective way to reduce that pain.”

“Our review helps clinicians use this evidence more confidently and consistently in practice.”

The findings land in a context where preventable pain and stress still contribute to early life morbidity: globally, neonatal deaths account for nearly half of all under‑five mortality, with the first days of life recognised by agencies such as UNICEF and the World Health Organization as a uniquely vulnerable period for brain and organ development. Improving routine pain management around common procedures is increasingly being framed as part of basic quality of care for newborns, not an optional add‑on.

What the Evidence Shows

• Population: more than 2,700 neonates across 29 randomized trials, including both preterm and term infants in a variety of hospital settings.
• Procedure: venepuncture and other brief needle‑based procedures common in newborn care, such as blood sampling and routine screening tests.
• Primary outcome: validated neonatal pain scores during the procedure and at 30-60 seconds post‑insertion.
• Comparators: no intervention, water, standard comfort care; secondary comparisons with pacifiers and skin‑to‑skin care.
• Safety: no reported harmful side effects such as gagging or apnoea in included studies, although authors note that rare events may still be under‑detected in small trials.

For health‑system leaders, the message is that sucrose is not an experimental intervention but a repeatedly tested, low‑cost option that can be integrated into existing neonatal quality and safety programs.

Why Standardising Pain Care for Newborns Still Lags

Newborns experience pain intensely due to immature regulation, and repeated exposure can affect growth and neurodevelopment. Yet practice remains inconsistent from well‑baby nurseries to intensive care units. “What stood out to me when doing this review was the wide variation in how sucrose was given to newborns.” Variation reflects local protocols, training, pharmacy preparation practices, and differing interpretations of evidence.

At a governance level, these inconsistencies interact with broader pressures: neonatal units are tasked with meeting national quality metrics and accreditation standards on pain assessment, while working within constrained staffing and pharmacy capacity. Where sucrose is not explicitly written into clinical pathways or order sets, its use can default to individual clinician preference rather than institutional policy.

Operational Considerations for Hospitals

For hospital executives and neonatal leaders, the review points toward operational steps that move sucrose‑based pain relief from “good idea” to reliably delivered standard of care.

• Clinical pathways: embed sucrose for brief needle procedures within neonatal order sets and peri‑procedure checklists, alongside non‑pharmacologic comfort measures, so its use is prompted as part of routine workflow rather than dependent on ad hoc decisions.
• Measurement and documentation: adopt validated neonatal pain scales (for example, PIPP‑R or NIPS) and record scores at baseline, during, and after procedures to support quality improvement, audit, and external reporting.
• Pharmacy and supply chain: ensure standardized, quality‑assured oral sucrose preparations with clear labeling and barcoding to reduce administration errors and to allow usage to be tracked across services.
• Workforce readiness: train nursing, phlebotomy, and neonatal teams on when sucrose is indicated, contraindication screening, and documentation workflows, including how to integrate sucrose with skin‑to‑skin contact and other comfort measures.
• Data feedback: use dashboards to track utilization, pain scores, and any adverse event reports across units and shifts, feeding into hospital‑wide patient‑safety committees.

Equity, Safety, and System‑Level Oversight

Because sucrose is inexpensive and simple to administer, it also raises questions of equity and accountability: if a low‑tech intervention can reduce avoidable pain, which systems are ensuring it reaches every eligible baby?

• Equity: low‑cost, low‑complexity interventions can narrow gaps in pain management between high‑resource and resource‑constrained settings if supplies and protocols are made universally available through national essential‑medicines lists and basic newborn‑care packages.
• Family‑centred care: integrate parental presence and soothing strategies with staff‑led measures to reduce distress without shifting clinical responsibility onto families. Clear communication that sucrose is evidence‑based can also help maintain trust.
• Safety governance: incorporate sucrose into neonatal medication safety reviews, incident‑reporting systems, and routine audits even where adverse events are rare, so that dosing ranges and contraindications remain under regular oversight.
• Accreditation alignment: hospital pain‑assessment and management standards apply across age groups, and neonatal policies should explicitly codify procedural pain care. In many jurisdictions, these standards are shaped by national regulators and by professional accreditation bodies that increasingly view pain control as a core patient‑rights issue.

At the policy level, guidance from the World Health Organization on quality of care for newborns and mothers is already influencing how countries write national neonatal standards; these frameworks call for systematic pain assessment and humane management as part of basic facility readiness. In parallel, rights‑based instruments such as the UN Convention on the Rights of the Child have helped move the idea that newborns deserve protection from avoidable suffering into the language of law and regulation.

Clinical Guidance Landscape and Remaining Gaps

• Consensus: non‑pharmacologic analgesia, including small‑volume oral sweet solutions, is widely endorsed for brief procedures in neonates when clinically appropriate, and is increasingly referenced in national and regional neonatal‑care guidelines.
• Implementation gap: heterogeneity in dosing, timing, and delivery devices highlights the need for unit‑level protocols and consistent staff training so that babies receive similar protection from pain regardless of which ward or clinician is on duty.
• Research needs: head‑to‑head comparisons with skin‑to‑skin care, durability of effects beyond the first minute, and standardized outcome reporting would strengthen future guidance and help regulators and professional bodies translate trial data into clearer, enforceable standards.

For ministries of health, hospital boards, and professional colleges, the Cochrane review offers both reassurance and a challenge: the science behind sucrose for procedural pain is increasingly solid, but whether every newborn actually benefits from it will depend on decisions made far beyond the bedside.